Monday, January 02, 2006

Breakthrough for MS

Neurological Disorders Channel
Reported January 6, 2006

Breakthrough for MS

Breakthrough for MS
Click a viewing speed on the right to watch Breakthrough for MS!
Click here to watch Breakthrough for MS in low speed: Use with an Internet connection using a modem.
Click here to watch Breakthrough for MS in high speed: Use with a broadband Internet connection.
FREE! Download
Windows Media Player

DALLAS (Ivanhoe Broadcast News) -- Multiple sclerosis can leave its victims unable to move and in constant pain. It's an autoimmune disease that wrecks havoc on the central nervous system. In some cases, no treatment works. Now, a new therapy stops the disease's progression and gets patients out of bed and back on their feet.

On her 40th birthday, Andra Litman was taken down a path unthinkable. "Unless you're in this body, I don't know how you can begin to imagine," she says.

Doctors diagnosed this artist, attorney, and mother of two with multiple sclerosis, a disease that left her unable to even turn over in bed. Then she started a new treatment. She was out of a wheelchair and on her feet in one month.

Breakthrough for MSNeurologist Olaf Stuve, M.D., Ph.D., says the cancer drug rituximab (Rituxan) is the first treatment to target the B cells in patients with MS, and it could be the first effective treatment for patients when nothing else works.

"The response to the Rituxan in those patients were really dramatic, in terms of not only stopping disease progression, but really helping the patient to recover some of the neurological function," Dr. Stuve, of UT Southwestern Medical Center in Dallas, tells Ivanhoe.

Instead of a daily or weekly injection, rituximab requires two infusions every six months. White spots, or lesions on a patient's brain before treatment, are hallmarks of MS. After treatment, they are gone.

Dr. Stuve says, "I think it will be a very effective therapy and probably more effective than what we have available at this time."

Breakthrough for MSLitman says, "The first thought every morning when I woke up for four years was, 'Is it a shot night?'" Now, she can tune her thoughts to what matters most.

Since rituximab only targets one aspect of the immune system, it poses fewer side effects than standard treatments. Dr. Stuve is just beginning a study on using rituximab to treat primary-progressive MS (PPMS), a specific form that affects 10 percent of patients and for which there are no effective treatments.

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.

If you would like more information, please contact:

Aline McKenzie
Office of News and Communications
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9060
(214) 648-3404
aline.mckenzie@utsouthwestern.edu
http://www.utsouthwestern.edu

Related Articles in Archives:


IVANHOE EXTRAS




Subscribe
Medical Alerts!

[ Back to Neurological Disorders Channel Home ]

MEDICAL ALERT!
Don't you want to be notified by e-mail every time there is a breakthrough on Neurological Disorders? This is the only Web site that will do this for you. Click here to sign up.
BOOKSTORE
Visit our bookstore for the Editor's picks on Neurological Disorders-related books.
[ click here ]
EDITOR'S CHOICE
New Hope for MS -- Full-Length Doctor's Interview

Delaying Parkinson’s Progression

Catching Alzheimer’s Disease Early


Home | What's New | News Flash | Discussion | Search/Archives | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Affiliates | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.

http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=12855

0 Comments:

Post a Comment

<< Home